Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.78 |
| ▸ | CBL | P22681 | 14/20 | 0.54 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30311255 | 1.00 | CBLB (0.78) | CBLBCBLCBLC | |
| SCHEMBL26106133 | 1.00 | CBLB (0.78) | CBLBCBLCBLC | |
| SCHEMBL26482318 | 1.00 | CBLB (0.78) | CBLBCBLCBLC | |
| SCHEMBL26480604 | 0.96 | CBLB (0.80) | CBLBCBLCBLC | |
| SCHEMBL26480815 | 0.94 | CBLB (0.70) | CBLBCBLCBLC | |
| SCHEMBL26485788 | 0.94 | CBLB (0.76) | CBLBCBLCBLC | |
| SCHEMBL26480599 | 0.94 | CBLB (0.76) | CBLBCBLCBLC | |
| SCHEMBL26480812 | 0.94 | CBLB (0.69) | CBLBCBLCBLC | |
| SCHEMBL26480809 | 0.94 | CBLB (0.71) | CBLBCBLCBLC | |
| SCHEMBL26480811 | 0.94 | CBLB (0.69) | CBLBCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2023217067-A1 | ENGINEERED IMMUNE EFFECTOR CELL AND USE THEREOF IN COMBINATION WITH CBL-B INHIBITOR | 上海先博生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.